IL17A and neoplasm: Although Vδ2 T cell therapy could significantly slow down the progression of liver cancer by its anti‐tumour immunity, another tumour‐infiltrated IL‐17‐producing γδ T cells exhibit as a tumour‐promoting function by inducing angiogenesis, making the role of tumour‐infiltrated‐γδ T cells more complicated.5, 6